$SURG
SurgePays, Inc. Stock $surg

$surg Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000149315223016407 Filed on May 11, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$35.89M	$34.78M	$21.14M
YoY Change	28.14%	64.49%	92.39%
Cost Of Revenue	$25.86M	$27.08M	$18.51M
YoY Change	0.18%	46.33%	87.72%
Gross Profit	$10.03M	$7.694M	$2.634M
YoY Change	357.59%	192.16%	133.16%
Gross Profit Margin	27.94%	22.13%	12.46%
Selling, General & Admin	$3.823M	$2.989M	$3.513M
YoY Change	25.82%	-14.9%	16.33%
% of Gross Profit	38.13%	38.85%	133.38%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$70.38K	$70.38K	$171.1K
YoY Change	149.73%	-58.86%	-21.51%
% of Gross Profit	0.7%	0.91%	6.5%
Operating Expenses	$3.823M	$2.989M	$3.684M
YoY Change	25.82%	-18.85%	13.78%
Operating Profit	$6.203M	$4.705M	-$1.050M
YoY Change	-831.83%	-548.04%	-50.19%
Interest Expense	-$150.0K	$400.0K	-$194.8K
YoY Change	-71.78%	-305.31%	-90.92%
% of Operating Profit	-2.42%	8.5%
Other Income/Expense, Net	-$145.6K	-$159.3K	$0.00
YoY Change	227.79%		-100.0%
Pretax Income	$6.060M	$4.546M	-$1.245M
YoY Change	-779.42%	-465.13%	-74.15%
Income Tax
% Of Pretax Income
Net Earnings	$5.966M	$4.546M	-$1.212M
YoY Change	-713.13%	-475.01%	-74.82%
Net Earnings / Revenue	16.62%	13.07%	-5.73%
Basic Earnings Per Share	$0.42	$0.32	-$0.10
Diluted Earnings Per Share	$0.40	$0.31	-$100.5K
COMMON SHARES
Basic Shares Outstanding	14.16M shares	14.12M shares	12.06M shares
Diluted Shares Outstanding	15.08M shares	14.54M shares	12.06M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.190M	$8.862M	$3.443M
YoY Change	-40.38%	157.4%	114.85%
Cash & Equivalents	$5.188M	$8.862M	$3.443M
Short-Term Investments
Other Short-Term Assets	$170.0K	$170.0K	$239.4K
YoY Change	285.93%	-29.01%	4.9%
Inventory	$18.09M	$15.52M	$3.076M
Prepaid Expenses	$167.7K	$170.0K
Receivables	$10.29M	$9.660M	$5.644M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$33.73M	$34.21M	$12.40M
YoY Change	48.29%	175.87%	385.6%
LONG-TERM ASSETS
Property, Plant & Equipment	$502.6K	$573.0K	$666.9K
YoY Change	-43.36%	-14.08%	-36.08%
Goodwill	$1.667M	$1.667M
YoY Change	0.0%
Intangibles	$2.453M	$2.617M
YoY Change	-21.04%
Long-Term Investments	$400.0K	$387.2K	$418.1K
YoY Change	-11.82%	-7.38%	22.67%
Other Assets
YoY Change
Total Long-Term Assets	$6.211M	$6.353M	$5.399M
YoY Change	-7.9%	17.68%	-13.43%
TOTAL ASSETS
Total Short-Term Assets	$33.73M	$34.21M	$12.40M
Total Long-Term Assets	$6.211M	$6.353M	$5.399M
Total Assets	$39.94M	$40.57M	$17.80M
YoY Change	35.44%	127.89%	102.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.890M	$7.609M	$7.015M
YoY Change	-56.3%	8.47%	337.25%
Accrued Expenses	$40.00K	$40.38K	$36.87K
YoY Change	6.02%	9.52%	-84.34%
Deferred Revenue
YoY Change
Short-Term Debt	$1.150M	$2.240M	$1.547M
YoY Change	-85.08%	44.73%	46.29%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$18.48M	$25.65M	$8.917M
YoY Change	-13.39%	187.63%	-40.45%
LONG-TERM LIABILITIES
Long-Term Debt	$4.520M	$4.550M	$6.100M
YoY Change	-18.82%	-25.41%	119.95%
Other Long-Term Liabilities	$380.0K	$389.0K	$429.4K
YoY Change	-9.43%	-9.4%	-70.05%
Total Long-Term Liabilities	$4.902M	$4.939M	$6.529M
YoY Change	-18.12%	-24.36%	55.22%
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.48M	$25.65M	$8.917M
Total Long-Term Liabilities	$4.902M	$4.939M	$6.529M
Total Liabilities	$23.38M	$30.59M	$15.41M
YoY Change	-14.42%	98.44%	-19.64%
SHAREHOLDERS EQUITY
Retained Earnings	-$25.29M	-$31.26M
YoY Change	-32.21%
Common Stock	$14.29K	$14.18K
YoY Change	15.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$16.35M	$9.854M	$2.387M
YoY Change
Total Liabilities & Shareholders Equity	$39.94M	$40.57M	$17.80M
YoY Change	35.44%	127.89%	102.51%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	$5.966M	$4.546M	-$1.212M
YoY Change	-713.13%	-475.01%	-74.82%
Depreciation, Depletion And Amortization	$70.38K	$70.38K	$171.1K
YoY Change	149.73%	-58.86%	-21.51%
Cash From Operating Activities	-$2.650M	$2.866M	-$3.324M
YoY Change	-1610.06%	-186.23%	-3.25%
INVESTING ACTIVITIES
Capital Expenditures	$0.00		-$11.40K
YoY Change	-100.0%		335.11%
Acquisitions
YoY Change
Other Investing Activities	-$120.0K	-$157.0K
YoY Change	-85.0%
Cash From Investing Activities	-$120.0K	-$157.0K	-$11.40K
YoY Change	-89.09%	1277.58%	335.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-910.0K	-$882.3K	494.4K
YoY Change	-114.71%	-278.47%	-88.68%
NET CHANGE
Cash From Operating Activities	-2.650M	$2.866M	-3.324M
Cash From Investing Activities	-120.0K	-$157.0K	-11.40K
Cash From Financing Activities	-910.0K	-$882.3K	494.4K
Net Change In Cash	-3.680M	$1.826M	-2.841M
YoY Change	-169.94%	-164.3%	-405.94%
FREE CASH FLOW
Cash From Operating Activities	-$2.650M	$2.866M	-$3.324M
Capital Expenditures	$0.00		-$11.40K
Free Cash Flow	-$2.650M	$2.866M	-$3.312M
YoY Change	-657.32%	-186.52%	-3.51%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	SURG	Amortization Of Internal Use Software Development Costs AmortizationOfInternalUseSoftwareDevelopmentCosts		usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2022Q1	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware		usd
CY2022Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
CY2023Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
CY2022Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q1	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction		usd
CY2022Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-25183	usd
CY2022Q4	SURG	Accumulated Depreciation AccumulatedDepreciation		usd
CY2022Q1	SURG	Amortization Of Internal Use Software Development Costs AmortizationOfInternalUseSoftwareDevelopmentCosts		usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree		usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour		usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
CY2021Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValue		usd
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001392694
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Vested And Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVestedAndExercisable		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	572991	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	643373	usd
CY2023Q1	us-gaap	Notes Receivable Net NotesReceivableNet	176851	usd
CY2022Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsUnvested		shares
CY2022Q4	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Unvested SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueUnvested
CY2022	SURG	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsUnvested
CY2022Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueUnvested		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2023Q1	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Granted SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueGranted
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2023Q1	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Exercise SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueExercise
CY2023Q1	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValue		usd
CY2023Q1	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Vested And Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVestedAndExercisable		usd
CY2023Q1	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsUnvested		shares
CY2023Q1	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Unvested SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueUnvested
CY2023Q1	SURG	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsUnvested
CY2023Q1	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueUnvested		usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-40992
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	SURGEPAYS, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-0550352
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	3124 Brother Blvd
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 104
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Bartlett
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	TN
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	38133
CY2023Q1	dei	City Area Code CityAreaCode	901
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	302-9587
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	14161855	shares
CY2023Q1	us-gaap	Cash Cash	8862085	usd
CY2022Q4	us-gaap	Cash Cash	7035654	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9659552	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9230365	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	15521969	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	11186242	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	169952	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	111524	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	34213558	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	27563785	usd
CY2022Q4	us-gaap	Notes Receivable Net NotesReceivableNet	176851	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2616601	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-31257765	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2779977	usd
CY2023Q1	SURG	Internal Use Software Development Costs Net InternalUseSoftwareDevelopmentCostsNet	511959	usd
CY2022Q4	SURG	Internal Use Software Development Costs Net InternalUseSoftwareDevelopmentCostsNet	387180	usd
CY2023Q1	us-gaap	Goodwill Goodwill	1666782	usd
CY2022Q4	us-gaap	Goodwill Goodwill	1666782	usd
CY2023Q1	us-gaap	Investments Investments	387235	usd
CY2022Q4	us-gaap	Investments Investments	354206	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	420665	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	431352	usd
CY2023Q1	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	5780093	usd
CY2022Q4	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	5796348	usd
CY2023Q1	us-gaap	Assets Assets	40566642	usd
CY2022Q4	us-gaap	Assets Assets	34003506	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	7202711	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	5784374	usd
CY2023Q1	SURG	Accounts Payable And Accrued Expenses Related Party Current AccountsPayableAndAccruedExpensesRelatedPartyCurrent	405948	usd
CY2022Q4	SURG	Accounts Payable And Accrued Expenses Related Party Current AccountsPayableAndAccruedExpensesRelatedPartyCurrent	1728721	usd
CY2023Q1	SURG	Installment Sale Liability InstallmentSaleLiability	15044897	usd
CY2022Q4	SURG	Installment Sale Liability InstallmentSaleLiability	13018184	usd
CY2023Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	713321	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	243110	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	40384	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	39490	usd
CY2023Q1	us-gaap	Notes Payable Current NotesPayableCurrent	1131564	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1542033	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	25646975	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	23464062	usd
CY2023Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	4026413	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	4493798	usd
CY2023Q1	SURG	Notes Payable Non Current NotesPayableNonCurrent	470378	usd
CY2022Q4	SURG	Notes Payable Non Current NotesPayableNonCurrent	474846	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	388971	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	399413	usd
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4938897	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5421191	usd
CY2023Q1	us-gaap	Liabilities Liabilities	30585872	usd
CY2022Q4	us-gaap	Liabilities Liabilities	28885253	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14176914	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14176914	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14116832	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14116832	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	14177	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	14117	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	41097399	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	40780707	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3551321	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-35804106	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	9853811	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4990718	usd
CY2023Q1	us-gaap	Minority Interest MinorityInterest	126959	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	127535	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9980770	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5118253	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	40566642	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	34003506	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	34776443	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	21141372	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	27081960	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	18507741	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2989421	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3683782	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	30071381	usd
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	22191523	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	4705062	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1050151	usd
CY2023Q1	us-gaap	Interest Expense Other InterestExpenseOther	192326	usd
CY2022Q1	us-gaap	Interest Expense Other InterestExpenseOther	169645	usd
CY2023Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	33029	usd
CY2022Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-25183	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-159297	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-194828	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	4545765	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-1244979	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-576	usd
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-32645	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	4546341	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1212334	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.32
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.31
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14131276	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12063834	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14535222	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12063834	shares
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5118253	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	307458	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	9294	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-576	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	4546341	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9980770	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3551321	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	9294	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1826431	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	38953	usd
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-32645	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1212334	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1212334	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2354589	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2354589	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	4545765	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-1244979	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	233758	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	171068	usd
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	10687	usd
CY2022Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	23952	usd
CY2023Q1	SURG	Amortization Of Internal Use Software Development Costs AmortizationOfInternalUseSoftwareDevelopmentCosts	32265	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	316752	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	9294	usd
CY2023Q1	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	33029	usd
CY2022Q1	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	-25183	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	429187	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2394231	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4335727	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1283767	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	58428	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	239400	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1418337	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-957443	usd
CY2023Q1	SURG	Increase Decrease In Accounts Payable And Accrued Liabilities Related Party IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParty	-1322773	usd
CY2022Q1	SURG	Increase Decrease In Accounts Payable And Accrued Liabilities Related Party IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParty	-20187	usd
CY2023Q1	SURG	Increase Decrease In Installment Sale Liability Net IncreaseDecreaseInInstallmentSaleLiabilityNet	2026713	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	470211	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	41450	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-9548	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-22030	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2865796	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3323556	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11401	usd
CY2023Q1	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	157044	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-157044	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11401	usd
CY2023Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	467385	usd
CY2022Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	500000	usd
CY2023Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	410468	usd
CY2023Q1	SURG	Repayments Of Short Term Debt Including Notes Payable RepaymentsOfShortTermDebtIncludingNotesPayable	4468	usd
CY2022Q1	SURG	Repayments Of Short Term Debt Including Notes Payable RepaymentsOfShortTermDebtIncludingNotesPayable	5613	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-882321	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	494387	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2840570	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7035654	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6283496	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8862085	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3442926	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	100074	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	8552	usd
CY2022Q1	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	38953	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	4546341	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2865796	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-31257765	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9980770	usd
CY2023Q1	SURG	Working Capital WorkingCapital	8556583	usd
CY2023Q1	us-gaap	Cash Cash	8862085	usd
CY2023Q1	us-gaap	Reimbursement From Limited Partnership Investment ReimbursementFromLimitedPartnershipInvestment	100	usd
CY2023Q1	SURG	Reimbursement Cost Per Customer ReimbursementCostPerCustomer	30	usd
CY2023Q1	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	0	usd
CY2022Q1	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	57770	usd
CY2023Q1	us-gaap	Goodwill Goodwill	1666782	usd
CY2022Q4	us-gaap	Goodwill Goodwill	1666782	usd
CY2023Q1	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2022Q1	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2023Q1	SURG	Notes Receivable Gross Due Remainder Of Fiscal Year NotesReceivableGrossDueRemainderOfFiscalYear	52227	usd
CY2023Q1	SURG	Notes Receivable Gross Due In Next Twelve Months NotesReceivableGrossDueInNextTwelveMonths	89532	usd
CY2023Q1	SURG	Notes Receivable Gross Due In Year Two NotesReceivableGrossDueInYearTwo	44766	usd
CY2023Q1	us-gaap	Notes Receivable Gross NotesReceivableGross	186525	usd
CY2023Q1	SURG	Less Interest Receivable LessInterestReceivable	9674	usd
CY2023Q1	us-gaap	Notes Receivable Net NotesReceivableNet	176851	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	21141372	usd
CY2022Q1	SURG	Percentage Of Total Revenues PercentageOfTotalRevenues	1	pure
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	653507	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84B_eus-gaap--UseOfEstimates_zz9C8c0Vab95" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zkDjCHoxmv73">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparing financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates, and those estimates may be material.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant estimates during the three months ended March 31, 2023 and 2022, respectively, include, allowance for doubtful accounts and other receivables, inventory reserves and classifications, valuation of loss contingencies, valuation of derivative liabilities, valuation of stock-based compensation, estimated useful lives related to intangible assets, capitalized internal-use software development costs, and property and equipment, implicit interest rate in right-of-use operating leases, uncertain tax positions, and the valuation allowance on deferred tax assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2023Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	17525	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	17525	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	653507	usd
CY2023Q1	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	15521969	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	11186242	usd
CY2023Q1	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2022	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2023Q1	us-gaap	Deferred Revenue DeferredRevenue	713321	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	243110	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	34776443	usd
CY2023Q1	SURG	Percentage Of Total Revenues PercentageOfTotalRevenues	1	pure
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	653507	usd
CY2023Q1	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	usd
CY2023Q1	us-gaap	Investments Investments	387235	usd
CY2022Q4	us-gaap	Investments Investments	354206	usd
CY2023Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	33029	usd
CY2023Q1	us-gaap	Advertising Expense AdvertisingExpense	32336	usd
CY2022Q1	us-gaap	Advertising Expense AdvertisingExpense	86637	usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5693295	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5884928	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	4546341	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14131276	shares
CY2023Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	403946	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14535222	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.32
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.31
CY2023Q1	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	491589	usd
CY2022Q1	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	2426090	usd
CY2023Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_84D_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_znPcSwKnYJ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zB5kbeS57bN6">Reclassifications</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no material effect on the consolidated results of operations, stockholders’ equity, or cash flows.</span></p>
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	490130	usd
CY2023Q1	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1006286	usd
CY2022Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1006286	usd
CY2023Q1	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	82752	usd
CY2022Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	82752	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1089038	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1089038	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	516047	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	445665	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	572991	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	643373	usd
CY2022Q2	us-gaap	Property Plant And Equipment Fair Value Disclosure PropertyPlantAndEquipmentFairValueDisclosure	711400	usd
CY2022Q2	us-gaap	Payments For Software PaymentsForSoftware	300000	usd
CY2022Q2	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	85000	shares
CY2022Q2	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	411400	usd
CY2022Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	4.84
CY2023Q1	us-gaap	Depreciation Depreciation	70382	usd
CY2022Q1	us-gaap	Depreciation Depreciation	7691	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5753520	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5753520	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-3136919	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-2973543	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2616601	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2779977	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	163376	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	163376	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	165950	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2616601	usd
CY2023Q1	SURG	Accumulated Depreciation AccumulatedDepreciation	32265	usd
CY2023Q1	SURG	Property Plant And Equipment PropertyPlantAndEquipment	511959	usd
CY2022Q4	SURG	Property Plant And Equipment PropertyPlantAndEquipment	387180	usd
CY2023Q1	SURG	Amortization Of Internal Use Software Development Costs AmortizationOfInternalUseSoftwareDevelopmentCosts	32265	usd
CY2023Q1	SURG	Finite Lived Intangible Asset Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetAmortizationExpenseRemainderOfFiscalYear	96795	usd
CY2023Q1	SURG	Finite Lived Intangible Assets Amortization Expense Next Twelve Month FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonth	181408	usd
CY2023Q1	SURG	Finite Lived Intangible Asset Amortization Expense Year Two FiniteLivedIntangibleAssetAmortizationExpenseYearTwo	181408	usd
CY2023Q1	SURG	Finite Lived Intangible Asset Amortization Expense Year Three FiniteLivedIntangibleAssetAmortizationExpenseYearThree	52348	usd
CY2023Q1	SURG	Finite Lived Intangible Assets FiniteLivedIntangibleAssets	511959	usd
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1131185	usd
CY2022	SURG	Forgiveness Of Loan ForgivenessOfLoan	-518167	usd
CY2022	SURG	Repayments Of Notes Receivable From Related Parties RepaymentsOfNotesReceivableFromRelatedParties	11754	usd
CY2022	SURG	Long Debt Reclassified To Receivable LongDebtReclassifiedToReceivable	-126418	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	474846	usd
CY2023Q1	SURG	Repayments Of Notes Receivable From Related Parties RepaymentsOfNotesReceivableFromRelatedParties	4468	usd
CY2023Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	470378	usd
CY2022	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	524143	usd
CY2021	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	377743	usd
CY2021	us-gaap	Debt Instrument Frequency Of Periodic Payment DebtInstrumentFrequencyOfPeriodicPayment	Monthly payments are $3,566/month
CY2022	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	270745	shares
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	115404	usd
CY2023Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	12000	shares
CY2023Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P3Y
CY2023Q1	us-gaap	Interest Expense InterestExpense	400000	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	100000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	2239714	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	4068868	usd
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y1M28D
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	10680	usd
CY2023Q1	SURG	Long Term Debt Maturities Repayments Of Principal After Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour	470378	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	6789640	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	10687	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	23952	usd
CY2023Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	5385	usd
CY2022Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	5868	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	16072	usd
CY2022Q1	us-gaap	Lease Cost LeaseCost	29820	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	420665	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	431352	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	40384	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	39490	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	388971	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	399413	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	429355	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	438903	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	3401	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	16.00
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	9548	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	22030	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y3M
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y2M26D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.05	pure
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.05	pure
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	45361	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	61876	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	63460	usd
CY2023Q1	SURG	Lessee Operating Lease Liability Payments Due After Two LesseeOperatingLeaseLiabilityPaymentsDueAfterTwo	349178	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	519875	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	90520	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	429355	usd
CY2023Q1	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	100000	usd
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Voting Rights CommonStockVotingRights	Voting at 1 vote per share
CY2023Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	60082	shares
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	307458	usd
CY2022	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	200000	shares
CY2022Q4	SURG	Net Effect On Stockholders Deficit NetEffectOnStockholdersDeficit	0	usd
CY2022Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	711400	usd
CY2022	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	300000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	17004	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.00
CY2021	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term3 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3	P5Y1M28D
CY2021Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Options Un Vested And Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnVestedAndExercisableNumber	13603	shares
CY2021Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Options Unvested And Nonexercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAndNonexercisable	16.00
CY2022Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value Vested And Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValueVestedAndExercisable	10026387	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	5286	shares
CY2021	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term4 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4	P5Y1M28D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	17004	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.00
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y1M28D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	6801	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	16.00
CY2022	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term3 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3	P4Y1M28D
CY2022Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Options Un Vested And Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnVestedAndExercisableNumber	10203	shares
CY2022Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Options Unvested And Nonexercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAndNonexercisable	16.00
CY2022	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term4 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4	P4Y1M28D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	17004	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.00
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y11M1D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	11902	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	16.00
CY2023Q1	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term3 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3	P3Y11M1D
CY2023Q1	SURG	Share Based Compensation Arrangement By Share Based Payment Award Options Un Vested And Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnVestedAndExercisableNumber	5101	shares
CY2023Q1	SURG	Share Based Compensation Arrangement By Share Based Payment Award Options Unvested And Nonexercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAndNonexercisable	16.00
CY2023Q1	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term4 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4	P3Y11M1D
CY2023Q1	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold	9294	usd
CY2022Q1	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold	9294	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	34076	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P0Y11M1D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	6082984	shares
CY2021Q4	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue	8.68
CY2021	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms	P2Y11M4D
CY2021Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable	5852984	shares
CY2021Q4	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Exercisable SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueExercisable	8.70
CY2021	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Terms Exercisable1 ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermsExercisable1	P2Y10M6D
CY2021Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsUnvested	230000	shares
CY2021Q4	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Unvested SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueUnvested	8.00
CY2021	SURG	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsUnvested	P4Y10M6D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	189000	shares
CY2022	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Granted SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueGranted	4.73
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	498850	shares
CY2022	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Exercise SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueExercise	6.49
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	91743	shares
CY2022	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Forfeitured SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueForfeitured	40.02
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	5681392	shares
CY2022Q4	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue	5.05
CY2022	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms	P1Y10M6D
CY2022Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValue	10026387	usd
CY2022Q4	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable	5681392	shares
CY2022Q4	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Exercisable SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueExercisable	5.05
CY2022	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Terms Exercisable1 ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermsExercisable1	P1Y10M6D
CY2023Q1	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Forfeitured SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueForfeitured	34.28
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	5676106	shares
CY2023Q1	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue	5.03
CY2023Q1	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms	P1Y7M9D
CY2023Q1	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable	5676106	shares
CY2023Q1	SURG	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Exercisable SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueExercisable	5.03
CY2023Q1	SURG	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Terms Exercisable1 ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermsExercisable1	P1Y7M9D
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	51000	shares
CY2022	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	115404	usd
CY2023Q1	us-gaap	Revenues Revenues	34776443	usd
CY2022Q1	us-gaap	Revenues Revenues	21141372	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	27081960	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	18507741	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	2989421	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	3683782	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	4705062	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1050151	usd
CY2023Q1	us-gaap	Assets Assets	40566642	usd
CY2022Q4	us-gaap	Assets Assets	34003506	usd
CY2023Q1	us-gaap	Liabilities Liabilities	30585872	usd
CY2022Q4	us-gaap	Liabilities Liabilities	28885253	usd
CY2023Q1	us-gaap	Proceeds From Sales Of Assets Investing Activities ProceedsFromSalesOfAssetsInvestingActivities	25000000	usd
CY2023Q1	SURG	Sales Of Asset Description SalesOfAssetDescription	The agreement may be extended by a period of one (1) year upon mutual consent.
CY2023Q1	SURG	Sales Of Asset Percentage SalesOfAssetPercentage	0.0985	pure
CY2023Q1	SURG	Installment Sale Credit Description InstallmentSaleCreditDescription	3 month rolling average of 70% of the installment sale credit amount.
CY2023Q1	SURG	Prepayment Penalty Description PrepaymentPenaltyDescription	The Company is subject to a cancellation fee of 3% during the first year and 2% during the second year.
CY2023Q1	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	2000	usd
CY2023Q1	SURG	Default Rate Description DefaultRateDescription	For any unpaid amounts under this agreement, the Company is subject to a fee of 1.35% per month (16.2% annualized).
CY2023Q1	us-gaap	Line Of Credit Facility Commitment Fee Percentage LineOfCreditFacilityCommitmentFeePercentage	0.02	pure
CY2023Q1	us-gaap	Line Of Credit Facility Commitment Fee Amount LineOfCreditFacilityCommitmentFeeAmount	5000000	usd
CY2023Q1	us-gaap	Line Of Credit Facility Commitment Fee Description LineOfCreditFacilityCommitmentFeeDescription	For example, if the initial installment sale credit amount is $15,000,000, the credit availability fee would be $300,000 (2%). Any subsequent increase of $5,000,000 or more would result in an additional fee of $100,000 (2%). Commitment fees are paid over a period of 12 months as part of the Seller’s monthly invoicing.
CY2023Q1	SURG	Installment Sale Liability InstallmentSaleLiability	15044897	usd
CY2022Q4	SURG	Installment Sale Liability InstallmentSaleLiability	13018184	usd
CY2023Q1	us-gaap	Professional Fees ProfessionalFees	131000	usd
CY2022Q1	us-gaap	Professional Fees ProfessionalFees	0	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001493152-23-016407-index-headers.html	Edgar Link	pending
0001493152-23-016407-index.html	Edgar Link	pending
0001493152-23-016407.txt	Edgar Link	pending
0001493152-23-016407-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
surg-20230331.xsd	Edgar Link	pending
surg-20230331_cal.xml	Edgar Link	unprocessable
surg-20230331_def.xml	Edgar Link	unprocessable
surg-20230331_lab.xml	Edgar Link	unprocessable
surg-20230331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SURG
SurgePays, Inc. Stock $surg

2023 Q2 Form 10-Q Financial Statement

#000149315223016407 Filed on May 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SURG SurgePays, Inc. Stock $surg

2023 Q2 Form 10-Q Financial Statement

#000149315223016407 Filed on May 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SURG
SurgePays, Inc. Stock $surg